MedPath

Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome

Not Applicable
Completed
Conditions
Diarrhea
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Other: Gluten free diet
Other: Gluten rich diet
Registration Number
NCT01094041
Lead Sponsor
Mayo Clinic
Brief Summary

The specific hypotheses are:

Gluten supplementation for four weeks increases small intestinal permeability and accelerates colonic transit in patients with irritable bowel syndrome with diarrhea (IBS-D) or functional diarrhea (FD) who are HLA-DQ2 positive.

Detailed Description

The study design is a double-blind, randomized, controlled, parallel-group, 6-week study comparing the effects of gluten rich versus gluten free diets in diarrhea or diarrhea predominant IBS patients. All participants will keep a daily bowel pattern diary throughout the study. All participants will have negative serum tissue transglutaminase (TTg) assay, and anti-endomysial antibody test, if TTg is positive or equivocal. All participants will have the following studies performed both before and after the 4-week dietary intervention:

1. Stool samples to check markers of inflammation such as fecal calprotectin.

2. Blood samples to check markers of inflammation and for genetic testing.

3. After ingestion of the mannitol, lactulose and sucralose sugars, urine samples to indirectly measure small intestinal and colonic permeability.

4. After sedation, upper gastrointestinal endoscopy and flexible sigmoidoscopy to obtain 6 mucosal biopsies from the small bowel and sigmoid colon for immunohistochemical analysis.

5. Scintigraphy to measure gastrointestinal transit.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Gluten free dietGluten free diet-
Gluten rich dietGluten rich diet-
Primary Outcome Measures
NameTimeMethod
Small bowel permeability0 - 2 hours post sugar ingestion

Excretion of mannitol 0-2 hours after liquid formulation

Colonic permeability2 -24 hours post sugars ingestion

Cumulative excretion of mannitol at 2-24 hours after liquid

Colonic transit24 hours

Colonic transit geometric center at 24 hours

Secondary Outcome Measures
NameTimeMethod
Gastric emptying0-2 hours

Gastric emptying T1/2

Small bowel inflammatory response4 weeks

Duodenal mucosal immunocyte count in lamina propria

Stool frequency and consistency6 weeks

Bowel pattern diary

Colon transit6-12 hours

Ascending colon emptying T1/2

Colonic permeability8 to 24 hours after ingestion of sugars

Hourly excretion of mannitol

Small bowel transit time6 hours

Colonic filling at 6 hours (%)

Colonic inflammatory response4 weeks

Sigmoid colon mucosal immunocyte count in lamina propria

Trial Locations

Locations (1)

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath